Concurrent treatment with selective serotonin reuptake inhibitors (SSRIs) and non-steroidal anti-inflammatory drugs (NSAIDs) “substantially” increases the risk of gastrointestinal bleeding compared with either drug used alone, according to
by Mark Greener
https://www.pharmatimes.com/news/ssris_and_nsaids_combo_raises_risk_of_gi_bleed_991087Neurological, psychiatric, malignancies, infections and other diseases affecting the central nervous system (CNS) are already major pharmaceutical markets. And a recent paper in Drug Discovery Today remarks that drugs acting on the CNS represent the
by Mark Greener
https://www.pharmatimes.com/news/new_approach_overcomes_blood-brain_barrier_989964The pharmaceutical and biotechnology sectors increasingly employ nanotechnology’s unique properties to solve diagnostic, R&D and formulation problems. But a new survey, published in Nature Nanotechnology, highlights numerous communication gaps
by Mark Greener
https://www.pharmatimes.com/news/get_the_message_across_small_is_beautiful_991450Lamictal (lamotrigine) XR, GSK’s enteric-coated, slow-release formulation of the leading antiepileptic drug, is an effective, well-tolerated treatment for partial seizures, according to a study in the latest issue of Neurology. The study gives the
by Mark Greener
https://www.pharmatimes.com/news/new_data_provide_boost_for_gsks_lamictal_xr_991113Wyeth/Amgen's etanercept (Enbrel) and Abbott’s adalimumab (Humira) are both effective, well-tolerated treatments for juvenile rheumatoid arthritis, according to research presented this week at the American College of Rheumatology’s (ACR) Annual
by Mark Greener
https://www.pharmatimes.com/news/enbrel_and_humira_are_effective,_well_tolerated_in_juvenile_ra_991314Clinical studies of inhaled corticosteroids funded by the pharmaceutical industry are less likely to report adverse effects than those funded in other ways, a new study published in the Archives of Internal Medicine shows. - News - PharmaTimes
by Mark Greener
https://www.pharmatimes.com/news/drug_company_steroid_trials_less_likely_to_report_adverse_events_991199Human African trypanosomiasis, Chagas disease, Buruli ulcer and many other conditions that cause death, disability and economic destitution for millions of people across the developing world don’t attract the research effort their public health
by Mark Greener
https://www.pharmatimes.com/news/developing_world_diseases_not_attracting_research_effort_989517Some commentators question the ethics of performing clinical studies or basic research in developing countries. Is it ethical to conduct or benefit from research in another country if the studies would be unlawful, or generally regarded as unethical,
by Mark Greener
https://www.pharmatimes.com/news/research_abroad_is_it_legal_and_ethical_989456If you were dying, you would probably want to try everything to prolong your life. And an American pressure group plans to ask the US Supreme Court to determine whether terminally ill patients have a constitutional right to access experimental drugs
by Mark Greener
https://www.pharmatimes.com/news/should_terminally_ill_patients_be_able_to_use_phase_ii_drugs_by_right_990848Genotype, drugs and other modifiable factors, such as smoking, appear to interact to increase the risk of obesity and metabolic syndrome in patients with schizophrenia, according to a study presented at the 20th Congress of the European College of
by Mark Greener
https://www.pharmatimes.com/news/genetic_risk_factors_point_way_to_metabolic_disease_risk_with_antipsychotics_991176
